Pharmaceutical

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Bristol Myers Squibb (BMS) has concluded the acquisition of Karuna Therapeutics for an equity value totalling $14bn.

Mar 20, 2024 - 00:00
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
Bristol Myers Squibb (BMS) has concluded the acquisition of Karuna Therapeutics for an equity value totalling $14bn.
Read the original article

Tags:

Previous Article

Microsoft and NVIDIA expand collaboration in healthcare innovation

Next Article

No Proof of Brain Injury in ‘Havana Syndrome’ Patients

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals’s RPA-501?

Risk adjusted net present value: What is the current va...

Nov 18, 2023

STAT+: Sanofi scoops up U.S. biotech Inhibrx for up to $2.2 billion as it seeks to bolster pipeline

STAT+: Sanofi scoops up U.S. biotech Inhibrx for up to ...

Jan 24, 2024

Opinion: Congress could stop free public access to government-funded research

Opinion: Congress could stop free public access to gove...

Sep 28, 2023